The (pro)renin receptor ((P)RR) is a critical component of the renin-angiotensin system (RAS), serving as a multifunctional protein involved in a variety of physiological and pathophysiological processes. It binds both renin and its precursor, prorenin, thus facilitating the conversion of angiotensinogen to angiotensin I, which is a precursor to several bioactive peptides, including angiotensin II (Ang II), a potent vasoconstrictor involved in regulating blood pressure and fluid balance. Beyond its well-documented role in the RAS, the (P)RR is also implicated in cellular signaling pathways that influence cell proliferation, apoptosis, and autophagy. This receptor operates within a complex regulatory network, modulating the balance between extracellular matrix remodeling and tissue repair, as well as contributing to the pathogenesis of cardiovascular diseases, kidney disorders, and metabolic dysfunctions. The diversity of the (P)RR's functions underscores its significance as a target for understanding the molecular mechanisms underlying various physiological conditions and disease states.
Activation of the (pro)renin receptor ((P)RR) occurs through the binding of its ligands, renin, and prorenin, which induces a conformational change that increases the catalytic efficiency of renin in converting angiotensinogen to angiotensin I. This ligand-receptor interaction not only initiates the cascade of reactions leading to the production of Ang II but also activates intracellular signaling pathways, such as the mitogen-activated protein kinase (MAPK) pathway, which are critical for cell growth, differentiation, and survival. Additionally, the binding of prorenin to the (P)RR has been shown to unlock new functions for prorenin, independent of its enzymatic activity, by activating intracellular signals that contribute to tissue fibrosis and inflammation. The complexity of the (P)RR's role in mediating both systemic and local effects within the RAS and beyond emphasizes the receptor's versatility in regulating physiological responses and its potential impact on disease progression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Angiotensin II, Human | 4474-91-3 | sc-363643 sc-363643A sc-363643B sc-363643C | 1 mg 5 mg 25 mg 100 mg | $51.00 $100.00 $310.00 $690.00 | 3 | |
This peptide hormone acts through its receptor to activate the renin-angiotensin pathway, which may indirectly activate ATP6AP2, which is known to bind renin and prorenin. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
An angiotensin II receptor antagonist, which can increase renin release, potentially leading to increased interaction with ATP6AP2. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
This adenylate cyclase activator increases cAMP levels, potentially affecting pathways where ATP6AP2 serves a role in cell signaling. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective phosphodiesterase inhibitor. By increasing cAMP levels, it may influence cell signaling pathways involving ATP6AP2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor. Given ATP6AP2's role in PI3K/Akt signaling, LY294002 could indirectly modulate ATP6AP2 function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor that can affect cell migration and adhesion, potentially influencing ATP6AP2's role in these processes. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
An inhibitor of the TGF-beta signaling pathway, potentially affecting ATP6AP2's role in Wnt signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can influence autophagy, a process in which ATP6AP2 has been implicated. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
A v-ATPase inhibitor that can influence lysosomal acidification, a process in which ATP6AP2 serves a role. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
An autophagy inhibitor, potentially affecting ATP6AP2's role in this process. | ||||||